Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linifanib vs sorafenib in advanced hepatocellular carcinoma
jRCT2080221053Phase 3
- Sponsor
- Abbott Laboratories
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of linifanib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Abbott Laboratories.
02
Drugs
linifanib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080221053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221053.